-+ 0.00%
-+ 0.00%
-+ 0.00%

MaxCyte Reports Q4 Revenue Around $6.7M Vs $9.3M Est, Full-Year Revenue Near $30M Vs $35.41M Est

Benzinga·01/12/2026 13:18:27
Listen to the news

MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today provided a preliminary update on financial results for the fourth quarter and full year ended December 31, 2025.

Preliminary Unaudited Fourth Quarter and Full Year 2025 Results

  • Core revenue in the fourth quarter is expected to be between $6.6 million and $6.7 million.
  • Core revenue for the full year is expected to be between $29.5 million and $29.6 million.
  • Strategic Platform License (SPL) program-related revenue in the fourth quarter is expected to be between $0.4 million and $0.6 million.
  • SPL program-related revenue for the full year is expected to be between $3.3 million and $3.5 million.

Total cash, cash equivalents, and investments as of December 31, 2025, is expected to be approximately $155.6 million.